Studying The Therapeutic Effect Of NEO 212 Nasopharyngeal Carcinoma
Therapeutic Effect Of TMZ-POH On Human Nasopharyngeal Carcinoma Depends On Reactive Oxygen Species Accumulation
Authors: Li Xie1, Xingguo Song1, Wei Guo2, Xingwu Wang1, Ling Wei1, Yang Li1, Liyan Lv1, Weijun Wang3, Thomas C. Chen3, and Xianrang Song1
NeOnc Technologies conducted a study to determine the initial efficacy impact of its NEO 212 formulation for treating Nasopharyngeal Carcinoma (NPC). NPC is a common head and neck cancer that currently has no efficient chemotherapeutic agents for its treatment. Although fairly uncommon in Western nations with an incidence rate of one case for every 100,000 people each year, in South Asia, the Middle East, and North Africa this rate dramatically jumps to 21 cases per 100,000 people with a median survival rate of only 7.2 to 22 months.
NeOnc Technologies NEO 212, a conjugate formulation of Temozolomide (TMZ) and Peryllil Alcohol (POH), has been shown to provide increased efficacy in treating brain-based cancers such as glioblastoma where the ability to deliver therapeutics passed the Blood-Brain Barrier is needed.
In the study to verify the cytotoxicity of NEO 212 in NPC, four NPC cell lines CNE1, CNE2, HNE2, and SUME-α were employed in our study, which was treated with several concentrations of the individual constituents of TMZ and POH, TMZ alone and POH alone as well as an equimolar mix of NEO 212 for 48 hours. Then the cell viability was determined by MTT assay.
The results showed that NEO 212 inhibited the proliferation of CNE1, CNE2, HNE2,
and SUME-α better when compared to its individual constituents (TMZ, POH) and their combination (TMZ plus POH) in a dose-dependent manner significantly. Furthermore, a colony formation assay was also carried out, which demonstrated more potent inhibition of colony formation capability triggered by TMZ-POH than by its constituents and their combination. Taken together, the data in this study supported the inhibitory role in NPC cell growth and colony formation.